Gossamer Bio Earnings Call Transcripts
Fiscal Year 2026
-
The PROSERA phase III trial in PAH showed seralutinib improved 6MWD but narrowly missed statistical significance in the overall population due to a high placebo response, especially in Latin America. Clinically meaningful and statistically significant benefits were observed in high-risk and CTD subgroups, with a manageable safety profile.
Fiscal Year 2025
-
Seralutinib’s phase 3 Prosera trial is set for a key data readout in February, with a focus on sicker patients and a differentiated safety profile. Commercial launch is targeted for late Q2 2027, with expansion into PH-ILD and a strengthened pipeline through recent asset acquisition.
-
Major phase 3 data for seralutinib in PAH is expected in February, with a second phase 3 in PH-ILD planned by year-end, targeting a combined market over $20 billion. Seralutinib's strong safety and efficacy profile, plus the addition of RT234, positions the pipeline for global leadership.
-
Transitioning to commercialization, the company is preparing for a 2027 launch of seralutinib, with robust phase 3 trials in PAH and PH-ILD. Strong efficacy, safety, and operational synergies are expected to support market entry and expansion into new indications.
-
Copperwood is advancing toward construction with full permits, detailed engineering, and strong community and legislative support. Environmental mitigation and metallurgical testing are underway, with project financing targeted for early 2026 and new federal funding opportunities expected.
-
PROSERA phase III enrollment is nearly complete, with top-line results expected in February 2026. Financials remain strong, supporting operations through 2027, while seralutinib advances in both PAH and PH-ILD, targeting large unmet needs and significant commercial potential.
-
Seralutinib is advancing through late-stage trials in PAH and PH-ILD, with top-line data expected this year and launches targeted for 2027 and 2029. The drug is positioned for best-in-class safety and long-term use, with a strong market outlook and robust financial backing.
-
Phase III enrollment for pulmonary hypertension is on track, with top-line data expected in Q4 and a 2027 launch targeted. Seralutinib differentiates itself with strong safety, efficacy, and imaging data, and a global enrollment strategy positions it well against competitors.
-
Seralutinib, an inhaled therapy for pulmonary hypertension, has shown sustained efficacy and a favorable safety profile in clinical trials, positioning it as a strong competitor to existing treatments. Phase III data are expected in late 2024, with significant market potential and strong financial backing.
Fiscal Year 2024
-
PROSERA enrollment is on track for Q2 2025 completion, with data expected in Q4. Seralutinib is positioned for broad use in PAH, supported by robust safety and efficacy data, and commercial launch preparations are underway with Chiesi. PH-ILD program is advancing with regulatory alignment expected in 2025.
-
Seralutinib is advancing in global phase III trials for PAH and PH-ILD, with promising efficacy and safety data from earlier studies. Enrollment is strong, aided by competitive dynamics, and a major commercial partnership with Chiesi supports global strategy. Cash runway extends into 2027.
-
Seralutinib shows durable efficacy and safety in PAH, with phase III PROSERA enrolling globally and targeting sicker patients. The Chiesi partnership accelerates PH-ILD development and expands market reach, while regulatory alignment and strong trial design support future growth.